Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Inflammatory Bowel Disease Susceptibility Gene C1ORF106 Regulates Intestinal Epithelial Permeability.

Manzanillo P, Mouchess M, Ota N, Dai B, Ichikawa R, Wuster A, Haley B, Alvarado G, Kwon Y, Caothien R, Roose-Girma M, Warming S, McKenzie BS, Keir ME, Scherl A, Ouyang W, Yi T.

Immunohorizons. 2018 May 30;2(5):164-171. doi: 10.4049/immunohorizons.1800027.

PMID:
31022698
2.

The Importance of Molecular Immune Investigation in Therapeutic Clinical Development for Biomarker Assessment.

Lamb CA, Mansfield JC, Kirby JA, Keir ME.

J Crohns Colitis. 2019 Jul 25;13(7):956-957. doi: 10.1093/ecco-jcc/jjy219. No abstract available.

3.

AlphaE Integrin Expression Is Increased in the Ileum Relative to the Colon and Unaffected by Inflammation.

Ichikawa R, Lamb CA, Eastham-Anderson J, Scherl A, Raffals L, Faubion WA, Bennett MR, Long AK, Mansfield JC, Kirby JA, Keir ME.

J Crohns Colitis. 2018 Nov 9;12(10):1191-1199. doi: 10.1093/ecco-jcc/jjy084.

4.

Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease.

Lamb CA, O'Byrne S, Keir ME, Butcher EC.

J Crohns Colitis. 2018 Aug 22;12(suppl_2):S653-S668. doi: 10.1093/ecco-jcc/jjy060. Review.

PMID:
29767705
5.

Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease.

Tang MT, Keir ME, Erickson R, Stefanich EG, Fuh FK, Ramirez-Montagut T, McBride JM, Danilenko DM.

Aliment Pharmacol Ther. 2018 Jun;47(11):1440-1452. doi: 10.1111/apt.14631. Epub 2018 Mar 30. Review.

6.

T Lymphocytes Expressing AlphaE Beta7 Integrin in Ulcerative Colitis: Associations With Cellular Lineage and Phenotype.

Lamb CA, Kirby JA, Keir ME, Mansfield JC.

J Crohns Colitis. 2017 Dec 4;11(12):1504-1505. doi: 10.1093/ecco-jcc/jjx097. No abstract available.

7.

αEβ7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis.

Lamb CA, Mansfield JC, Tew GW, Gibbons D, Long AK, Irving P, Diehl L, Eastham-Anderson J, Price MB, O'Boyle G, Jones DEJ, O'Byrne S, Hayday A, Keir ME, Egen JG, Kirby JA.

J Crohns Colitis. 2017 May 1;11(5):610-620. doi: 10.1093/ecco-jcc/jjw189.

8.

Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC.

Colombel JF, Keir ME, Scherl A, Zhao R, de Hertogh G, Faubion WA, Lu TT.

Gut. 2017 Dec;66(12):2063-2068. doi: 10.1136/gutjnl-2016-312307. Epub 2016 Sep 2.

9.

Reply.

Keir ME, Tew GW, Hackney JA.

Gastroenterology. 2016 Jul;151(1):214. doi: 10.1053/j.gastro.2016.05.045. Epub 2016 May 28. No abstract available.

PMID:
27243639
10.

Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.

Tew GW, Hackney JA, Gibbons D, Lamb CA, Luca D, Egen JG, Diehl L, Eastham Anderson J, Vermeire S, Mansfield JC, Feagan BG, Panes J, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, Kirby JA, Irving PM, De Hertogh G, Van Assche GA, Rutgeerts P, O'Byrne S, Hayday A, Keir ME.

Gastroenterology. 2016 Feb;150(2):477-87.e9. doi: 10.1053/j.gastro.2015.10.041. Epub 2015 Oct 30.

11.

Stratified medicine in inflammatory disorders: From theory to practice.

Arron JR, Townsend MJ, Keir ME, Yaspan BL, Chan AC.

Clin Immunol. 2015 Nov;161(1):11-22. doi: 10.1016/j.clim.2015.04.006. Epub 2015 Apr 28. Review.

PMID:
25934386
12.

Functional consequences of the macrophage stimulating protein 689C inflammatory bowel disease risk allele.

Kauder SE, Santell L, Mai E, Wright LY, Luis E, N'Diaye EN, Lutman J, Ratti N, Sa SM, Maun HR, Stefanich E, Gonzalez LC, Graham RR, Diehl L, Faubion WA Jr, Keir ME, Young J, Chaudhuri A, Lazarus RA, Egen JG.

PLoS One. 2013 Dec 23;8(12):e83958. doi: 10.1371/journal.pone.0083958. eCollection 2013.

13.

EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging.

Faubion WA Jr, Fletcher JG, O'Byrne S, Feagan BG, de Villiers WJ, Salzberg B, Plevy S, Proctor DD, Valentine JF, Higgins PD, Harris JM, Diehl L, Wright L, Tew GW, Luca D, Basu K, Keir ME.

Am J Gastroenterol. 2013 Dec;108(12):1891-900. doi: 10.1038/ajg.2013.354. Epub 2013 Oct 15. Erratum in: Am J Gastroenterol. 2014 May;109(5):780.

PMID:
24126633
14.

CD28 costimulation regulates genome-wide effects on alternative splicing.

Butte MJ, Lee SJ, Jesneck J, Keir ME, Haining WN, Sharpe AH.

PLoS One. 2012;7(6):e40032. doi: 10.1371/journal.pone.0040032. Epub 2012 Jun 29.

15.

The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.

Paterson AM, Brown KE, Keir ME, Vanguri VK, Riella LV, Chandraker A, Sayegh MH, Blazar BR, Freeman GJ, Sharpe AH.

J Immunol. 2011 Aug 1;187(3):1097-105. doi: 10.4049/jimmunol.1003496. Epub 2011 Jun 22.

16.

PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice.

Mueller SN, Vanguri VK, Ha SJ, West EE, Keir ME, Glickman JN, Sharpe AH, Ahmed R.

J Clin Invest. 2010 Jul;120(7):2508-15. doi: 10.1172/JCI40040. Epub 2010 Jun 14.

17.

IFN-alpha-induced upregulation of CCR5 leads to expanded HIV tropism in vivo.

Stoddart CA, Keir ME, McCune JM.

PLoS Pathog. 2010 Feb 19;6(2):e1000766. doi: 10.1371/journal.ppat.1000766.

18.

Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus.

Tew GW, Rabbee N, Wolslegel K, Hsieh HJ, Monroe JG, Behrens TW, Brunetta PG, Keir ME.

Lupus. 2010 Feb;19(2):146-57. doi: 10.1177/0961203309350752. Epub 2009 Nov 27.

PMID:
19946034
19.

Bridging Toll-like- and B cell-receptor signaling: meet me at the autophagosome.

Monroe JG, Keir ME.

Immunity. 2008 Jun;28(6):729-31. doi: 10.1016/j.immuni.2008.05.006.

20.

PD-1 and its ligands in tolerance and immunity.

Keir ME, Butte MJ, Freeman GJ, Sharpe AH.

Annu Rev Immunol. 2008;26:677-704. doi: 10.1146/annurev.immunol.26.021607.090331. Review.

PMID:
18173375
21.

Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles.

Menke J, Lucas JA, Zeller GC, Keir ME, Huang XR, Tsuboi N, Mayadas TN, Lan HY, Sharpe AH, Kelley VR.

J Immunol. 2007 Dec 1;179(11):7466-77.

22.

Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart.

Grabie N, Gotsman I, DaCosta R, Pang H, Stavrakis G, Butte MJ, Keir ME, Freeman GJ, Sharpe AH, Lichtman AH.

Circulation. 2007 Oct 30;116(18):2062-71. Epub 2007 Oct 15.

PMID:
17938288
23.

PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues.

Keir ME, Freeman GJ, Sharpe AH.

J Immunol. 2007 Oct 15;179(8):5064-70.

24.

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.

Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ.

Immunity. 2007 Jul;27(1):111-22. Epub 2007 Jul 12.

25.

PD-1 and its ligands in T-cell immunity.

Keir ME, Francisco LM, Sharpe AH.

Curr Opin Immunol. 2007 Jun;19(3):309-14. Epub 2007 Apr 12. Review.

PMID:
17433872
26.

Tissue expression of PD-L1 mediates peripheral T cell tolerance.

Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH, Sharpe AH.

J Exp Med. 2006 Apr 17;203(4):883-95. Epub 2006 Apr 10.

27.

Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes.

Keir ME, Latchman YE, Freeman GJ, Sharpe AH.

J Immunol. 2005 Dec 1;175(11):7372-9.

28.

The B7/CD28 costimulatory family in autoimmunity.

Keir ME, Sharpe AH.

Immunol Rev. 2005 Apr;204:128-43. Review.

PMID:
15790355
29.

Generation of CD3+CD8low thymocytes in the HIV type 1-infected thymus.

Keir ME, Rosenberg MG, Sandberg JK, Jordan KA, Wiznia A, Nixon DF, Stoddart CA, McCune JM.

J Immunol. 2002 Sep 1;169(5):2788-96.

30.

IFN-alpha secretion by type 2 predendritic cells up-regulates MHC class I in the HIV-1-infected thymus.

Keir ME, Stoddart CA, Linquist-Stepps V, Moreno ME, McCune JM.

J Immunol. 2002 Jan 1;168(1):325-31.

Supplemental Content

Support Center